Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 1,641 | 1,826 | 1,870 | 338 | 73,746 |
| Cost of Goods | 599 | 651 | 647 | 739 | 700 |
| Gross Profit | 1,042 | 1,175 | 1,223 | -401 | 73,046 |
| Operating Expenses | 147,740 | 127,989 | 131,102 | 129,454 | 153,922 |
| Operating Income | -146,099 | -126,163 | -129,232 | -129,116 | -80,176 |
| Interest Expense | 20,594 | 20,121 | 19,990 | 19,825 | 20,279 |
| Other Income | 5,990 | 3,552 | 8,652 | 8,748 | 97,896 |
| Pre-tax Income | -160,703 | -142,732 | -140,570 | -140,193 | -2,559 |
| Net Income Continuous | -160,703 | -142,732 | -140,570 | -140,193 | -2,559 |
| Minority Interests | -2,804 | -2,576 | -2,979 | -2,854 | 7,297 |
| Net Income | $-157,899 | $-140,156 | $-137,591 | $-137,339 | $-9,856 |
| EPS Basic Total Ops | -0.98 | -0.92 | -0.91 | -0.93 | -0.07 |
| EPS Basic Continuous Ops | -1.00 | -0.94 | -0.94 | -0.95 | -0.02 |
| EPS Diluted Total Ops | -0.98 | -0.92 | -0.91 | -0.93 | -0.07 |
| EPS Diluted Continuous Ops | -1.00 | -0.94 | -0.94 | -0.95 | -0.02 |
| EBITDA(a) | $-144,462 | $-124,530 | $-127,572 | $-127,471 | $-78,594 |